News & Insights
Besides sharing our hands-on expertise in projects, we regularly share industry insights, updates, and news.
News
Stay up to date with the latest news, press releases and events here!
OogFarma Partners with NecstGen for Cleanroom Rental Collaboration Supporting Patient Safety and Efficiency of Ophthalmic Therapy in the Netherlands.
This collaboration leverages NecstGen’s advanced GMP-compliant facilities to ensure safe and efficient delivery of anti-VEGF treatments for macular degeneration. Both companies share a mission to reduce healthcare costs while enhancing patient safety through innovative, ready-to-use medical solutions
NecstGen Invites You To The CGT Circle
NecstGen is delighted to host a CGT Circle event on October 16th at our site in Leiden supporting the CGT Circle’s mission to harness the collective power and experience of women in the field of Cell and Gene Therapy.
€10 Million Awarded to NecstGen, NTrans Technologies, LUMC, and Divvly to Transform Cell and Gene Therapies
A grant from IPCEI Med4Health will facilitate the development of advanced technologies to improve cell and gene therapy production.
Press Release: NecstGen Recurring Customer Pan Cancer T Secures € 4.25 Million Seed Extension
NecstGen Recurring Customer Pan Cancer T secures 4.25 million Euro seed extension and continues its path to the clinic to treat solid tumors.
Collaboration UMC Utrecht for Bone Regeneration Therapy
NecstGen and UMC Utrecht partner to advance bone regeneration therapy using MSC-derived spheroids, marking a significant step in regenerative medicine.
EIC Awards €2.5 Million Grant
Following a rigorous selection process by an expert panel, Trince, NecstGen, and IBSAL are proud to announce that their “Penphomet” project has been selected by The European Innovation Council (EIC) for a significant grant of €2.5 million.
NecstGen and Aarhus University Collaborate in Groundbreaking Initiative for GMP-Compliant Stem Cell Production
NecstGen, Netherlands, a pioneering biotechnology center and non-profit CDMO specialising in Gene and Cell therapy, is proud to announce its groundbreaking collaboration with the Center for Gene and Cellular Therapy at Aarhus University Hospital (AUH), Denmark.
NecstGen and ProteoNic Report Development of Improved Viral Vectors Through the Application of Premium 2G UNicTM Technology
NecstGen and ProteoNic announce the successful development of improved lentiviral vectors for Cell and Gene Therapy, leveraging ProteoNic’s premium 2G UNic™ technology.
Cline Scientific announces Letter of Intent with NecstGen for the manufacture of its stem cell therapy for damaged cartilage
Cline Scientific announces Letter of Intent with NecstGen for the manufacture of its stem cell therapy for damaged cartilage
bioMérieux partners with NecstGen
bioMérieux and NecstGen, collaborate to accelerate the development of Cell and Gene Therapies (CGT) through the provision of ‘state of the art’ and rapid quality and safety testing technologies that will allow safe and effective advanced therapeutics production.
Webinars
At NecstGen, we are dedicated to driving innovation and knowledge-sharing in the fields of gene and cell therapy. Our webinar series is designed to provide in-depth insights into cutting-edge topics, including CAR T cell therapies and induced pluripotent stem cells (iPSCs), two of the most promising areas in modern medicine.
Webinar Reducing Lentivirus Costs
Discover how our Design of Experiments (DOE) methodology optimises cost-efficiency in GMP manufacturing to turn a refined lab process into a scalable, GMP-ready protocol.
Webinar LV Process for CAR T
Shifting from traditional, ad hoc methodologies to a structured, data-based development approach to create a scalable, GMP-ready process.
Webinar CAR Therapy Today & Tomorrow
Explore available CAR therapies, differentiation, development challenges, and lessons learned from our expert scientist.
Webinar Product Quality For Cell Therapies
This session is all about building and testing strategies to set the groundwork for effective development and testing in your own work.
Webinar iPSC Banking & Derivation
iPSC Banking & Derivation Ever wondered how to transition from bench to GMP suitable processes in the iPSC-derived therapies field? Yes? Watch the webinar replay on iPSC Derivation & Banking.Key areas of focus include: Transitioning from Bench to GMP Suitable...
Stem Cells
Stem cells hold enormous potential for advancing regenerative medicine, with the ability to repair damaged tissues, treat degenerative diseases, and model complex conditions.
iPSC Reprogramming & Transdifferentiation
iPSC reprogramming and cell transdifferentiation offer exciting cellular science opportunities. Learn how these approaches are changing regenerative medicine and cellular therapy.
Differentiation of Human iPSCs
Human induced pluripotent stem cells (iPSCs) offer great potential for the future of medicine. We look into the world of human iPSCs, exploring their incredible promise and the critical significance of directing their development towards specialised cell lineages.
iPSC Development: Technical, Clinical, and Regulatory Hurdles
Induced pluripotent stem cells hold immense promise in revolutionising medicine through patient-specific therapies. However, their clinical development presents intricate challenges, including safety validation, differentiation complexities, and ethical considerations.
Exploring the Impact of iPSC-Derived Organoids on Biomedical Science
Discover the role of iPSC-derived organoids in biomedical science, advancing our understanding of human biology and opening doors.
The Ethical Advantages of iPSCs
Stem cell research has long been mired in ethical controversies, primarily around embryonic stem cell use, which involves complex moral and philosophical debates. The advent of iPSCs presents a turning point, promising a less contentious path forward in regenerative medicine.
IPSCs, what are they? And what is their potential?
What are iPSCs? And how can we harness induced Pluripotent Stem Cells’ potential for the betterment of patient care?
Cell and Gene Therapy companies in Europe
European Cell & Gene Therapy CompaniesAt NecstGen, we aim to support industry partnerships and growth. And to enable the next generation of therapies, it is pivotal to have oversight of the gene and therapy landscape to start from, which is why we created this...
Outsourcing Cell Therapy Manufacturing
Here are the questions you want to ask yourself when considering the outsourcing Cell Therapy Manufacturing to a CDMO. Do you have additional questions? Let us know!
Ex Vivo Gene Therapy
Ex vivo gene therapy is one of the most promising areas in the fight against genetic disorders. By modifying cells outside the body and then reintroducing them into the patient, this approach ensures a high degree of control and precision.
The First Stages of CAR T Cell Therapy Development
Chimeric Antigen Receptor (CAR) T cell therapy represents a transformative approach in medicine, particularly in oncology. This method offers personalised treatment by harnessing a patient's immune system to target and eliminate (cancer) cells. These novel therapies...
Cell and Gene Therapy companies in Europe
European Cell & Gene Therapy CompaniesAt NecstGen, we aim to support industry partnerships and growth. And to enable the next generation of therapies, it is pivotal to have oversight of the gene and therapy landscape to start from, which is why we created this...
European Landscape For Cell & Gene Therapy companies
At NecstGen, we aim to support industry partnerships and growth. And to enable the next generation of therapies, it is pivotal to have oversight of the gene and therapy landscape to start collaborations and partnerships so we can challenge today’s possibilities and enable the unthinkable, together.
Did you find what you were looking for?
If not, we would be happy to answer any questions you might have regarding our vacancies or life at NecstGen.
